Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers

Nu-3 represents a novel class of potent, fast-acting, broad-spectrum antimicrobials called Bisphosphocins®

SARASOTA, Fla., May 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT) a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin^® class, today announced positive antimicrobial resistance (AMR) data for its lead compound, Nu-3, which is being developed as a topically delivered treatment for infected diabetic foot ulcers (iDFU).

Nu-3 is one of a new class of antimicrobial compounds discovered by Lakewood-Amedex Biotherapeutics called the Bisphosphocin^® class, which are also being explored in pre-clinical studies as potential treatments for complicated urinary tract infection (cUTI) and pulmonary infections. The Bisphosphocin^® class of compounds have been shown in vitro to rapidly kill bacteria through a pH and concentration dependent destabilization of the bacterial cell membrane, typically achieving this effect in under one minute of exposure. This mechanism of action offers the potential to reduce the threat posed by antibiotic-resistant bacterial strains, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE), and others.

In laboratory studies using a serial passage of E. coli and MRSA in the presence of Nu-3 for 21 days, Nu-3 showed slightly increased Minimum Inhibitory Concentration (MIC) at the end of the experiment for E. coli and were unchanged for MRSA. In contrast, the MIC for the ciprofloxacin control had increased over 2,000-fold for E. coli and over 600-fold for MRSA. In addition, Nu-3 maintained its original MIC when assessed against the bacteria that had developed resistance to Ciprofloxacin, which implies that cross-resistance did not occur.

"In experiments designed to induce resistance, the Bisphosphocin class has maintained its in vitro efficacy and potency, demonstrating a very low potential for resistance development, which confers enormous potential for our Nu-3 candidate targeting iDFU, and more broadly, as we work towards solutions for antimicrobial resistance, a major health challenge for our society," said Kelvin Cooper, Ph.D., Chief Executive Officer at Lakewood-Amedex Biotherapeutics. "Notably, the AMR data support our understanding of the mechanism of the Bisphosphocin^® class of compounds, which we believe can provide a broad spectrum of activity against gram-positive, gram-negative, and multidrug-resistant organisms, and would provide a significant advantage over many existing antimicrobial classes."

The global AMR crisis is directly responsible for approximately 1.27 million deaths annually and contributes to nearly 5 million deaths worldwide. "Drug-resistant pathogens are a rising threat that have rendered many existing antibiotics ineffective, leading to increased mortality as well as higher healthcare costs and longer hospital stays," stated Thomas Balzer, MD, Ph.D., Chief Medical Officer and Senior Vice President, Clinical Development. "Of the approximately 830 million people who suffer from diabetes globally, about one third will develop a DFU in their life, of which about 50% will become infected, with many patients experiencing multiple infection events through their lives. We are developing Nu-3 to meet this very large, critically underserved treatment need."

About 15% to 20% of iDFU cases are caused by resistant pathogens, primarily MRSA underscoring the need for rapid and effective treatment in the early stage, including effective elimination of resistant pathogens to prevent disease progression and potentially devastating complications like amputations. For individual with diabetes, infections, especially when left untreated, are a risk factor for amputations, alongside the presence of conditions like peripheral arterial disease. The economic burden of DFU complications is significant, with the cost of care estimated at $80 billion in 2018 in the U.S., comparable to the cost of treating the five most expensive forms of cancer in total.

About Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.

Forward-Looking Statements

This press release may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Generally, the words "believe," "expect," "intsend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. Our Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause our Company's actual results to differ materially from historical experience and our present expectations or projections.

Relying on such statements involves risk, uncertainty and assumptions. These statements  are based on the current estimates and assumptions of the management of Lakewood‐Amedex Biotherapeutics Inc. as of the date of this press release and are subject to uncertainty and changes. All statements obtained in this press release are made only as of the date of this press release and Lakewood‐Amedex Biotherapeutics Inc. does not undertake any obligation to publicly update any forward‐looking statements.

Contact

Investor Relations

Tiberend Strategic Advisors, Inc.

David Irish

(231) 632-0002

dirish@tiberend.com

Media Relations

Tiberend Strategic Advisors, Inc.

Casey McDonald

(646) 577-8520

cmcdonald@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-positive-antimicrobial-resistance-data-for-lead-candidate-targeting-infected-diabetic-foot-ulcers-302759775.html

SOURCE Lakewood-Amedex Biotherapeutics Inc.